CTLA-4 gene study in children with new ITP
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial looks at a specific gene, CTLA-4, to see if variations are linked to how children first experience immune thrombocytopenia (ITP). It may help doctors understand why some kids get ITP and how to treat it better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a child between 1 and 18 years old
- You must have just been diagnosed with ITP (not had it for a long time)
- You or your parent must agree to join the study by signing a consent form
- The study is open to both boys and girls
- You cannot have ITP that is ongoing (lasting more than 3 months) or have had it before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) for people with chronic or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if this treatment can safely raise platelet counts and reduce bleeding risk.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This trial tests whether adding ianalumab to eltrombopag helps children with immune thrombocytopenia (ITP) who didn't get better with steroids. It aims to find a new option for kids whose platelet counts are low despite treatment.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This study looks back at medical records of people with newly diagnosed or persistent ITP (lasting up to 12 months) to understand how the condition is treated in real life. Anyone who received standard ITP treatments or none at all may be included.
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
Hear when a new ITP - Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.